About Our Company
Mark Rapoport - President & CEO
As part of the investor group that purchased TT&W, Mark Rapoport serves as the company’s President and Chief Executive Officer. Prior to TT&W, Rapoport served as Chief Operating Officer and Chief Financial Officer for Landacorp, Inc., a publicly traded population health management company providing software and disease management services to hospitals and health plans that was subsequently purchased by SHPS, Inc. Mr. Rapoport joined Landacorp from iXL, where he served as Senior Vice President, Controller. Additionally, he has also held key management positions for BellSouth Corporation. As Executive Director-Mergers & Acquisitions Accounting, he worked with the corporate development group for merger and acquisition activities. Mr. Rapoport also served as Vice President-Finance and Chief Financial Officer for BellSouth Entertainment, the company's video division. He also held several other senior financial management positions in business planning and market development in the BellSouth organization. Mr. Rapoport has worked as a certified public accountant with KPMG and earned his Master of Business Administration in Finance and Accounting from Emory University.
Troy Breiland - Vice President-Operations
Troy Breiland is a seasoned healthcare outsourcing executive with a strong record of performance in healthcare eligibility services. Over the years he has consistently demonstrated his ability to lead cross- functional teams in the design, development and launch of revenue cycle solutions and processes designed to maximize healthcare reimbursements. Troy joined TT& W form DECO Recovery Management, Landover, MD, where he served as director of operations. Prior that Troy worked for MedAssist, Inc. in a variety of positions, including area operations manager, training, and as a patient representative. Troy graduated Cum Laude from the University of Minnesota.
Board of Directors
Edward L. Cahill
Mr. Cahill is a Managing Partner of HLM Venture Partners. Mr. Cahill was a founding partner of Cahill, Warnock & Company (now Camden Partners), a Baltimore venture capital firm. Previously, Mr. Cahill was a Managing Director of Alex. Brown & Sons, where he headed the firm's Health Care group from 1986 through 1995. During his leadership at Alex. Brown & Sons, the firm underwrote public offerings or provided merger advisory services for over 200 health care companies, including the first outpatient surgery, rehabilitation and managed care companies to go public, and several leading biopharmaceutical companies. Mr. Cahill is a director of Animas Corporation (NASDAQ), Guava Technologies, Inc., Masimo Corporation, and Spinal Kinetics, Inc. and previously a director of Centene Corporation (NYSE), Spinal Concepts, OH+R, Automated Healthcare and Gene Medicine (NASDAQ). He also serves as a trustee of Johns Hopkins Medicine, Johns Hopkins Health System, and Mercy Health Services. Mr. Cahill received an AB from Williams College and a Master of Public and Private Management degree from Yale University.
Howard Cox
Mr. Cox is a partner of Greylock Partners, one of the nation's leading early-stage venture capital firms. Mr. Cox joined Greylock in 1971 after two years in the Office of the Secretary of Defense (Systems Analysis). He is a graduate of Princeton University, Columbia Law School and the Harvard Business School, and he is a former Chairman of the National Venture Capital Association. Mr. Cox currently serves on the board of Stryker. Among the boards he previously served on include the Boston Globe, American Medical Systems, AMISYS (acquired by McKessonHBOC), ISSCO (acquired by Computer Associates), Lunar (acquired by GE), Multimate, Rehab Systems (acquired by Novacare), Share Development (acquired by United Healthcare), United Publishers (acquired by NYNEX), VHA Long Term Care (acquired by ServiceMaster), and Vincam (acquired by ADP). He also led Greylock's investments in OTG Software (acquired by Legato), Meditech and Promega.
Thomas F. (Tad) O'Donnell, III
Mr. O’Donnell is a General Partner of HLM Venture Partners. He has been a general partner of various HLM venture capital limited partnerships since joining HLM in 1999. Previously, Mr. O’Donnell was a Vice President at General Catalyst and an Associate at Greylock. His venture investment experience has been focused on minority equity investments and recapitalizations of medical software, technology and specialty service companies. Prior to venture capital, Mr. O’Donnell was an investment banking analyst at Smith Barney. He is currently a board observer at Cord Blood Registry and Telephia. He previously served as board observer at Phase Forward (NASDAQ) and Symbion (NASDAQ), which both went public in 2004. In addition, Mr. O’Donnell serves as a director of Wing Aviation, class chair of the Harvard College Fund and a member of the Alumni Executive Committee of St. Mark's School. Mr. O’Donnell received an AB from Harvard College and an MBA from Harvard Business School.
